US5928893A - Monoclonal antibody specific for human 4-1BB and cell line producing same - Google Patents
Monoclonal antibody specific for human 4-1BB and cell line producing same Download PDFInfo
- Publication number
- US5928893A US5928893A US08/737,560 US73756096A US5928893A US 5928893 A US5928893 A US 5928893A US 73756096 A US73756096 A US 73756096A US 5928893 A US5928893 A US 5928893A
- Authority
- US
- United States
- Prior art keywords
- cells
- ser
- monoclonal antibody
- human
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 title claims abstract description 31
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 title claims abstract description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 27
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 19
- 210000004989 spleen cell Anatomy 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 40
- 108091033319 polynucleotide Proteins 0.000 abstract description 6
- 102000040430 polynucleotide Human genes 0.000 abstract description 6
- 239000002157 polynucleotide Substances 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 description 34
- 239000000427 antigen Substances 0.000 description 19
- 230000027455 binding Effects 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108010062580 Concanavalin A Proteins 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 229940125721 immunosuppressive agent Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000002627 4-1BB Ligand Human genes 0.000 description 4
- 108010082808 4-1BB Ligand Proteins 0.000 description 4
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- -1 OX-40 Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 3
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 3
- DXVOKNVIKORTHQ-GUBZILKMSA-N Glu-Pro-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O DXVOKNVIKORTHQ-GUBZILKMSA-N 0.000 description 3
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 3
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 3
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 3
- FOCSWPCHUDVNLP-PMVMPFDFSA-N His-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N FOCSWPCHUDVNLP-PMVMPFDFSA-N 0.000 description 3
- HNDWYLYAYNBWMP-AJNGGQMLSA-N Leu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N HNDWYLYAYNBWMP-AJNGGQMLSA-N 0.000 description 3
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 3
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 3
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 3
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 3
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 3
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 3
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 3
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000006472 autoimmune response Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 3
- 108010037850 glycylvaline Proteins 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108010031719 prolyl-serine Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 2
- GWNMUVANAWDZTI-YUMQZZPRSA-N Asn-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N GWNMUVANAWDZTI-YUMQZZPRSA-N 0.000 description 2
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- UEILCTONAMOGBR-RWRJDSDZSA-N Gln-Thr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UEILCTONAMOGBR-RWRJDSDZSA-N 0.000 description 2
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 2
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 2
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 2
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 2
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- YFXXRYFWJFQAFW-JHYOHUSXSA-N Phe-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YFXXRYFWJFQAFW-JHYOHUSXSA-N 0.000 description 2
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 2
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 2
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 2
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 2
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 2
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 description 2
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- XKXAZPSREVUCRT-BPNCWPANSA-N Ala-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 XKXAZPSREVUCRT-BPNCWPANSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 1
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 1
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 102000007499 CD27 Ligand Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- IVCOYUURLWQDJQ-LPEHRKFASA-N Gln-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O IVCOYUURLWQDJQ-LPEHRKFASA-N 0.000 description 1
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- LPCKHUXOGVNZRS-YUMQZZPRSA-N Gly-His-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O LPCKHUXOGVNZRS-YUMQZZPRSA-N 0.000 description 1
- DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- RUTZUJXAVNWLQP-BVSLBCMMSA-N Met-Tyr-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 RUTZUJXAVNWLQP-BVSLBCMMSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- NOFBJKKOPKJDCO-KKXDTOCCSA-N Phe-Ala-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NOFBJKKOPKJDCO-KKXDTOCCSA-N 0.000 description 1
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- BIWBTRRBHIEVAH-IHPCNDPISA-N Ser-Tyr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O BIWBTRRBHIEVAH-IHPCNDPISA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- XPYNXORPPVTVQK-SRVKXCTJSA-N Val-Arg-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)O)N XPYNXORPPVTVQK-SRVKXCTJSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 210000003293 antilymphocyte serum Anatomy 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000002978 thoracic duct Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR95/8176 | 1995-04-08 | ||
| KR19950008176 | 1995-04-08 | ||
| PCT/KR1996/000045 WO1996032495A1 (en) | 1995-04-08 | 1996-04-06 | Monoclonal antibody specific for human 4-1bb and cell line producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5928893A true US5928893A (en) | 1999-07-27 |
Family
ID=19411779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/737,560 Expired - Fee Related US5928893A (en) | 1995-04-08 | 1996-04-06 | Monoclonal antibody specific for human 4-1BB and cell line producing same |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5928893A (ja) |
| EP (1) | EP0766745B1 (ja) |
| JP (1) | JP2911056B2 (ja) |
| AT (1) | ATE226641T1 (ja) |
| DE (1) | DE69624436T2 (ja) |
| DK (1) | DK0766745T3 (ja) |
| ES (1) | ES2185770T3 (ja) |
| PT (1) | PT766745E (ja) |
| WO (1) | WO1996032495A1 (ja) |
Cited By (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6458934B1 (en) * | 1998-11-17 | 2002-10-01 | Lg Chemical Limited | Humanized antibody specific for human 4-1BB |
| US20020168719A1 (en) * | 1993-09-16 | 2002-11-14 | Indiana University Foundation | Receptor and related products and methods |
| US20030082157A1 (en) * | 1988-11-07 | 2003-05-01 | Kwon Byoung S. | Receptor and related products and methods |
| US20030096976A1 (en) * | 1998-11-17 | 2003-05-22 | Hong Hyo Jeong | Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies |
| US20030100745A1 (en) * | 1988-11-07 | 2003-05-29 | Advanced Research And Technology Institute, Inc. | Antibody for 4-1BB |
| US20030138422A1 (en) * | 2001-09-26 | 2003-07-24 | Jane Aghajanian | Antibody inhibitors of GDF-8 and uses thereof |
| US20040001863A1 (en) * | 1998-12-03 | 2004-01-01 | Shau-Chi Chi | Immortal cell line derived from grouper Epinephelus coioides and its applications therein |
| WO2004010947A2 (en) * | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| US20040109847A1 (en) * | 2002-07-15 | 2004-06-10 | Lieping Chen | Treatment and prophylaxis with 4-1BB-binding agents |
| WO2004055513A2 (en) * | 2002-12-16 | 2004-07-01 | Herbert Schwarz | Use of cd137 antagonists for the treatment of tumors |
| US20040136992A1 (en) * | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| US20060063923A1 (en) * | 1992-07-30 | 2006-03-23 | Kwon Byoung S | 4-1BB peptides and methods for use |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| US20060188439A1 (en) * | 2005-02-18 | 2006-08-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| US20080050366A1 (en) * | 2003-12-10 | 2008-02-28 | Greg Elson | Neutralizing antibodies and methods of use thereof |
| US20080118501A1 (en) * | 2005-10-21 | 2008-05-22 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
| US20090176317A1 (en) * | 2006-04-20 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Soluble B7-H1 |
| US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
| US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
| WO2011071883A1 (en) * | 2009-12-07 | 2011-06-16 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
| US20110200620A1 (en) * | 2004-10-06 | 2011-08-18 | Lieping Chen | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
| US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
| US8460927B2 (en) | 1999-11-30 | 2013-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 antibodies and method of use |
| US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
| US8772026B2 (en) | 2001-10-09 | 2014-07-08 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1 BB-binding agents |
| WO2015069703A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US9243059B2 (en) | 2013-03-12 | 2016-01-26 | Decimmune Therapeutics, Inc. | Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury |
| WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| WO2018098401A1 (en) | 2016-11-23 | 2018-05-31 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| US10167336B2 (en) | 2013-03-14 | 2019-01-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
| US10279038B2 (en) | 2017-07-11 | 2019-05-07 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
| US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
| WO2019136456A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019141268A1 (zh) * | 2018-01-22 | 2019-07-25 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及其医药用途 |
| WO2019160829A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
| WO2019190579A1 (en) | 2018-03-29 | 2019-10-03 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
| WO2020061429A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
| WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
| WO2020096986A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2020096927A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| WO2020096988A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020096682A2 (en) | 2018-08-31 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
| WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| WO2020205662A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Inc. | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| WO2021081378A1 (en) | 2019-10-25 | 2021-04-29 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2021108727A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Inc. | Method of producing tumor-reactive t cell composition using modulatory agents |
| WO2021118990A1 (en) | 2019-12-11 | 2021-06-17 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| WO2021167908A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
| WO2021218684A1 (zh) | 2020-04-29 | 2021-11-04 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226085A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2021226061A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2022076952A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CN114450306A (zh) * | 2019-07-26 | 2022-05-06 | Abl生物公司 | 抗egfr/抗4-1bb双特异性抗体及其用途 |
| WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| WO2022225981A2 (en) | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| US11981921B2 (en) | 2023-06-20 | 2024-05-14 | Iovance Biotherapeutics, Inc. | TIL expansion processes using specific cytokine combinations and/or AKTi treatment |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210669B1 (en) * | 1996-10-11 | 2001-04-03 | Bristol-Myers Squibb Co. | Methods and compositions for immunomodulation |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| CA2408408C (en) | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
| EP1388544A1 (en) * | 2002-07-31 | 2004-02-11 | D. Collen Research Foundation vzw | Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
| TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| US20210230287A1 (en) * | 2018-04-10 | 2021-07-29 | Wuxi Biologics (Shanghai) Co., Ltd. | A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof |
| CA3185200A1 (en) * | 2020-07-09 | 2022-01-13 | Lankeanau Institute For Medical Research | Compositions comprising antibodies to human ido-2 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5674704A (en) * | 1993-05-07 | 1997-10-07 | Immunex Corporation | Cytokine designated 4-IBB ligand |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2172165C (en) * | 1993-09-16 | 2003-12-02 | Byoung S. Kwon | Human receptor h4-1bb |
-
1996
- 1996-04-06 AT AT96909384T patent/ATE226641T1/de not_active IP Right Cessation
- 1996-04-06 WO PCT/KR1996/000045 patent/WO1996032495A1/en active IP Right Grant
- 1996-04-06 US US08/737,560 patent/US5928893A/en not_active Expired - Fee Related
- 1996-04-06 ES ES96909384T patent/ES2185770T3/es not_active Expired - Lifetime
- 1996-04-06 PT PT96909384T patent/PT766745E/pt unknown
- 1996-04-06 EP EP96909384A patent/EP0766745B1/en not_active Expired - Lifetime
- 1996-04-06 JP JP8530902A patent/JP2911056B2/ja not_active Expired - Fee Related
- 1996-04-06 DK DK96909384T patent/DK0766745T3/da active
- 1996-04-06 DE DE69624436T patent/DE69624436T2/de not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5674704A (en) * | 1993-05-07 | 1997-10-07 | Immunex Corporation | Cytokine designated 4-IBB ligand |
Non-Patent Citations (6)
| Title |
|---|
| Kahan, B. Cur. Opin. Immunol. 4: 553 560, 1992. * |
| Kahan, B. Cur. Opin. Immunol. 4: 553-560, 1992. |
| Lenschow, D. et al. J. Exp. Med. 181: 1145 1155, Mar. 1995. * |
| Lenschow, D. et al. J. Exp. Med. 181: 1145-1155, Mar. 1995. |
| Pollok, K. et al. J. Immunol. 150: 771 781, Feb. 1993. * |
| Pollok, K. et al. J. Immunol. 150: 771-781, Feb. 1993. |
Cited By (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091476A1 (en) * | 1988-11-07 | 2004-05-13 | Advanced Research And Technology Institute, Inc. | Methods of using human receptor protein 4-1BB |
| US6974863B2 (en) | 1988-11-07 | 2005-12-13 | Indiana University Research And Technology Corporation | Antibody for 4-1BB |
| US20030082157A1 (en) * | 1988-11-07 | 2003-05-01 | Kwon Byoung S. | Receptor and related products and methods |
| US20060002904A9 (en) * | 1988-11-07 | 2006-01-05 | Kwon Byoung S | Receptor and related products and methods |
| US20030100745A1 (en) * | 1988-11-07 | 2003-05-29 | Advanced Research And Technology Institute, Inc. | Antibody for 4-1BB |
| US6905685B2 (en) | 1988-11-07 | 2005-06-14 | Byoung S. Kwon | Methods of using antibodies to human receptor protein 4-1BB |
| US20060063923A1 (en) * | 1992-07-30 | 2006-03-23 | Kwon Byoung S | 4-1BB peptides and methods for use |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US20020168719A1 (en) * | 1993-09-16 | 2002-11-14 | Indiana University Foundation | Receptor and related products and methods |
| US8026353B2 (en) | 1993-09-16 | 2011-09-27 | Indiana University Research And Technology Corporation | Nucleic acid molecules encoding human 4-1BB |
| US6569997B1 (en) | 1995-03-23 | 2003-05-27 | Advanced Research And Technology Institute, Inc. | Antibody specific for H4-1BB |
| US20030096976A1 (en) * | 1998-11-17 | 2003-05-22 | Hong Hyo Jeong | Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies |
| US6458934B1 (en) * | 1998-11-17 | 2002-10-01 | Lg Chemical Limited | Humanized antibody specific for human 4-1BB |
| US20040001863A1 (en) * | 1998-12-03 | 2004-01-01 | Shau-Chi Chi | Immortal cell line derived from grouper Epinephelus coioides and its applications therein |
| US8460927B2 (en) | 1999-11-30 | 2013-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 antibodies and method of use |
| US8092798B2 (en) | 2001-09-26 | 2012-01-10 | Wyeth Llc | Method of increasing trabecular bone density in a patient in need thereof by an antibody against GDF-8 |
| US8710202B2 (en) | 2001-09-26 | 2014-04-29 | Wyeth Llc | Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity |
| US20110020330A1 (en) * | 2001-09-26 | 2011-01-27 | Wyeth | Antibody inhibitors of gdf-8 and uses thereof |
| US7731961B1 (en) | 2001-09-26 | 2010-06-08 | Wyeth | Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8 |
| US9505831B2 (en) | 2001-09-26 | 2016-11-29 | Wyeth Llc | Isolated cell comprising a nucleic acid encoding antibody inhibitors of gdf-8 and uses thereof |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US20030138422A1 (en) * | 2001-09-26 | 2003-07-24 | Jane Aghajanian | Antibody inhibitors of GDF-8 and uses thereof |
| US8772026B2 (en) | 2001-10-09 | 2014-07-08 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1 BB-binding agents |
| US20090068193A1 (en) * | 2002-07-15 | 2009-03-12 | Lieping Chen | Treatment And Prophylaxis With 4-1BB-Binding Agents |
| US20040109847A1 (en) * | 2002-07-15 | 2004-06-10 | Lieping Chen | Treatment and prophylaxis with 4-1BB-binding agents |
| WO2004010947A3 (en) * | 2002-07-30 | 2004-09-23 | Bristol Myers Squibb Co | Humanized antibodies against human 4-1bb |
| WO2004010947A2 (en) * | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
| US7214493B2 (en) | 2002-07-30 | 2007-05-08 | Bristol-Myers Squibb Company | Polynucleotides encoding humanized antibodies against human 4-1BB |
| US20040105855A1 (en) * | 2002-07-30 | 2004-06-03 | Kunkel Maria Jure | Humanized antibodies against human 4-1BB |
| US20050202022A1 (en) * | 2002-07-30 | 2005-09-15 | Kunkel Maria J. | Polynucleotides encoding humanized antibodies against human 4-1BB |
| US8529894B2 (en) | 2002-08-28 | 2013-09-10 | Immunex Corporation | Methods of reducing inflammation in cardiomyopathy |
| US20040136992A1 (en) * | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
| US20060121030A1 (en) * | 2002-12-16 | 2006-06-08 | Herbert Schwarz | Use of cd 137 antagonists for the treatment of tumors |
| WO2004055513A2 (en) * | 2002-12-16 | 2004-07-01 | Herbert Schwarz | Use of cd137 antagonists for the treatment of tumors |
| WO2004055513A3 (en) * | 2002-12-16 | 2004-09-16 | Herbert Schwarz | Use of cd137 antagonists for the treatment of tumors |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP2859901A1 (en) | 2003-04-02 | 2015-04-15 | Aduro GVAX Inc. | Cytokine-expressing cellular vaccine combinations |
| EP2574346A1 (en) | 2003-04-02 | 2013-04-03 | BioSante Pharmaceuticals, Inc. | Cytokine-expressing cellular vaccine combinations |
| US20050002916A1 (en) * | 2003-04-02 | 2005-01-06 | Karin Jooss | Cytokine-expressing cellular vaccine combinations |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US20080050366A1 (en) * | 2003-12-10 | 2008-02-28 | Greg Elson | Neutralizing antibodies and methods of use thereof |
| US8747833B2 (en) | 2004-10-06 | 2014-06-10 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
| US9803015B2 (en) | 2004-10-06 | 2017-10-31 | Mayo Foundation For Medical Education And Research | Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target |
| US20110200620A1 (en) * | 2004-10-06 | 2011-08-18 | Lieping Chen | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
| US11939378B2 (en) | 2004-10-06 | 2024-03-26 | Mayo Foundation For Medical Education And Research | Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target |
| US11242387B2 (en) | 2004-10-06 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target |
| US20110104049A1 (en) * | 2005-02-15 | 2011-05-05 | Gtc Biotherapeutics, Inc. | Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| US20060188439A1 (en) * | 2005-02-18 | 2006-08-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| US20080118501A1 (en) * | 2005-10-21 | 2008-05-22 | Gtc Biotherapeutics, Inc. | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use |
| US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
| US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| US20090176317A1 (en) * | 2006-04-20 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Soluble B7-H1 |
| US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
| US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
| US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
| US8324352B2 (en) | 2009-12-07 | 2012-12-04 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
| AU2010328359B2 (en) * | 2009-12-07 | 2015-02-05 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
| WO2011071883A1 (en) * | 2009-12-07 | 2011-06-16 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
| US9409977B2 (en) | 2013-03-12 | 2016-08-09 | Decimmune Therapeutics, Inc. | Humanized, anti-N2 antibodies |
| US9243059B2 (en) | 2013-03-12 | 2016-01-26 | Decimmune Therapeutics, Inc. | Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury |
| US10167336B2 (en) | 2013-03-14 | 2019-01-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US11136393B2 (en) | 2013-10-01 | 2021-10-05 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of Bim |
| US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
| WO2015069703A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
| US11504376B2 (en) | 2014-07-23 | 2022-11-22 | Mayo Foundation For Medical Education And Research | Targeting DNA-PKCS and B7-H1 to treat cancer |
| US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
| EP3744340A2 (en) | 2015-07-16 | 2020-12-02 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| WO2017009842A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| EP3943098A2 (en) | 2015-07-16 | 2022-01-26 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| US11667890B2 (en) | 2016-10-31 | 2023-06-06 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
| US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
| WO2018098401A1 (en) | 2016-11-23 | 2018-05-31 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
| US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
| US11433097B2 (en) | 2017-06-05 | 2022-09-06 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| WO2020117233A1 (en) | 2017-06-05 | 2020-06-11 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| US11819517B2 (en) | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| US10279039B2 (en) | 2017-07-11 | 2019-05-07 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US10434175B2 (en) | 2017-07-11 | 2019-10-08 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US10350292B1 (en) | 2017-07-11 | 2019-07-16 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US10279038B2 (en) | 2017-07-11 | 2019-05-07 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US10716851B2 (en) | 2017-07-11 | 2020-07-21 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US10279040B1 (en) | 2017-07-11 | 2019-05-07 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US11752207B2 (en) | 2017-07-11 | 2023-09-12 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| WO2019136456A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019141268A1 (zh) * | 2018-01-22 | 2019-07-25 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及其医药用途 |
| WO2019160829A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| WO2019190579A1 (en) | 2018-03-29 | 2019-10-03 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US11384337B2 (en) | 2018-04-27 | 2022-07-12 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US11866688B2 (en) | 2018-04-27 | 2024-01-09 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2020096682A2 (en) | 2018-08-31 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
| WO2020061429A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
| WO2020096927A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
| WO2020096986A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2020096988A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
| WO2020205662A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Inc. | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| CN114450306A (zh) * | 2019-07-26 | 2022-05-06 | Abl生物公司 | 抗egfr/抗4-1bb双特异性抗体及其用途 |
| CN114450306B (zh) * | 2019-07-26 | 2024-04-05 | Abl生物公司 | 抗egfr/抗4-1bb双特异性抗体及其用途 |
| WO2021081378A1 (en) | 2019-10-25 | 2021-04-29 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2021108727A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Inc. | Method of producing tumor-reactive t cell composition using modulatory agents |
| WO2021118990A1 (en) | 2019-12-11 | 2021-06-17 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| WO2021167908A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
| EP4050031A1 (en) | 2020-04-29 | 2022-08-31 | Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd. | Tetravalent bispecific antibody against pd-1/lag-3, preparation method therefor, and use thereof |
| EP4050028A1 (en) | 2020-04-29 | 2022-08-31 | Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd. | Tetravalent bispecific antibody against pd-1/tgf-beta, preparation method therefor, and use thereof |
| EP4047018A1 (en) | 2020-04-29 | 2022-08-24 | Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd. | Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof |
| WO2021218684A1 (zh) | 2020-04-29 | 2021-11-04 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226085A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2021226061A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076952A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| WO2022225981A2 (en) | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| US11981921B2 (en) | 2023-06-20 | 2024-05-14 | Iovance Biotherapeutics, Inc. | TIL expansion processes using specific cytokine combinations and/or AKTi treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| PT766745E (pt) | 2003-02-28 |
| JP2911056B2 (ja) | 1999-06-23 |
| JPH09509067A (ja) | 1997-09-16 |
| EP0766745B1 (en) | 2002-10-23 |
| DE69624436T2 (de) | 2003-08-28 |
| DK0766745T3 (da) | 2002-11-25 |
| ATE226641T1 (de) | 2002-11-15 |
| ES2185770T3 (es) | 2003-05-01 |
| EP0766745A1 (en) | 1997-04-09 |
| DE69624436D1 (de) | 2002-11-28 |
| WO1996032495A1 (en) | 1996-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5928893A (en) | Monoclonal antibody specific for human 4-1BB and cell line producing same | |
| AU784313B2 (en) | Recombinant anti-CD40 antibody and uses thereof | |
| US6210669B1 (en) | Methods and compositions for immunomodulation | |
| EP0741784B1 (en) | Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells | |
| US5639455A (en) | Immunosuppressant | |
| EP0675200B1 (en) | A FAS ligand, a fragment thereof and DNA encoding the same | |
| Aucouturier et al. | Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. | |
| KR100483494B1 (ko) | 감마 인터페론에 대한 인간화 항체 | |
| CA2439858C (en) | Graft rejection suppressors | |
| US20030103976A1 (en) | Anti-fas antibodies | |
| JP2002534441A (ja) | 抗ｃｄ３免疫毒素およびその治療的使用 | |
| JP2002506420A (ja) | 変異した不活化ＩｇＧ２ドメインおよびこれを組み込んだ抗ＣＤ３抗体 | |
| JPH05310596A (ja) | 抗体を含有する免疫抑制剤 | |
| RU2261723C2 (ru) | Молчащие анти-cd28-антитела и их применение | |
| AU757961B2 (en) | Anti-Fas antibodies | |
| US7622554B2 (en) | FAS ligand derived polypeptides | |
| WO2006135263A1 (en) | Fibroblast growth factor receptor-5 antibodies and methods for their use | |
| CA2128151A1 (en) | Receptors of interleukin-12 and antibodies | |
| KR100370744B1 (ko) | 임파구의 활성화 억제제 | |
| CZ294340B6 (cs) | Molekula protilátky proti Fas, způsob výroby, hostitelská buňka a prostředek | |
| US20040116675A1 (en) | Silenced anti-cd28 antibodies and use thereof | |
| KR100204733B1 (ko) | 인체 4-1비비 분자에 특이성이 있고 면역억제 효과를 갖는 모노클로날 항체 | |
| WO2001072334A2 (en) | Methods for treating disease with antibodies to cxcr3 | |
| JP2023504974A (ja) | 抗ｔｉｒｃ７抗原結合タンパク質 | |
| AU784729B2 (en) | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: LG CHEMICAL LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KANG, CHANG-YUIL;KIM, JOONG-GON;REEL/FRAME:008284/0140 Effective date: 19961031 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20070727 |